文献速递结核与非结核分枝杆菌

定量干扰素-γ释放试验在预测韩国军队结核病中的作用:一项回顾性队列研究

Quantitative interferon-gamma releasing assay in predicting tuberculosis in South Korean military: a retrospective cohort study.
PubMed 文献 · Clin Microbiol Infect · 2024-04-30

该回顾性队列研究基于韩国兵役厅数据库(2017年1月至2021年12月)和韩国军事医疗司令部报告的结核病病例(2017年1月至2023年6月),分析入伍前干扰素-γ释放试验(IGRA)结果与服役期间结核病(TBD)风险的关系。共筛查1 647 941人,29 574人IGRA阳性;在随访的9 219例未治疗阳性者、5 818例治疗阳性者和1 356 324例阴性者中,TBD发生率分别为130.1/10万人年、45.9/10万人年和2.8/10万人年。将IGRA阳性阈值从0.35 IU/mL提高至1.33 IU/mL,阳性预测值从0.2%升至0.4%(p 0.03),灵敏度从24%降至20%(p 0.69),需治疗人数从790.5降至415.3。作者认为在健康年轻军人群体中可考虑提高IGRA治疗潜伏性结核感染的阈值。

要点

  • 入伍前IGRA阳性者服役期间TBD风险高于阴性者。
  • 未治疗IGRA阳性者TBD发生率为130.1/10万人年,治疗者为45.9/10万人年。
  • 阈值升至1.33 IU/mL可提高阳性预测值并减少需治疗人数。

核心结论

  • 入伍前较高的IGRA水平与服役期间结核病风险相关。
  • 在健康年轻军人群体中,值得考虑提高IGRA治疗潜伏性结核感染的阈值。

研究设计与样本

  • 回顾性队列研究,分析韩国兵役厅数据库(2017年1月至2021年12月)的IGRA结果和韩国军事医疗司令部(2017年1月至2023年6月)报告的TBD病例。
  • 所有18个月兵役候选者在入伍前检查时接受IGRA,阳性者(≥0.35 IU/mL)被建议在入伍前接受TBI治疗。
  • 2017年至2021年共筛查1 647 941人,29 574人IGRA阳性。
  • 排除未入伍者(入伍前已患TBD)后,19 387人IGRA阳性,1 356 324人IGRA阴性;阳性者中4 351人因入伍时或之后中止或正在接受TBI治疗而被排除。
  • 随访包括9 219例未治疗阳性者、5 818例治疗阳性者和1 356 324例阴性者。

主要发现

  • IGRA阳性者中TBD发生22例(97.5/10万人年[95% CI, 61.1-147.7]),主要发生在未治疗组(18例,130.1/10万人年[95% CI, 77.1-205.7]),治疗组为4例(45.9/10万人年[95% CI 12.5-117.4])。
  • IGRA阴性组发生57例TBD(2.8/10万人年[95% CI, 2.2-3.6])。
  • 将IGRA cutoff从0.35 IU/mL提高至1.33 IU/mL,阳性预测值从0.2%升至0.4%(p 0.03),灵敏度从24%降至20%(p 0.69),需治疗人数从790.5降至415.3。

关键数值与推荐

  • IGRA阳性定义为≥0.35 IU/mL。
  • 提高cutoff至1.33 IU/mL时,阳性预测值0.2% vs. 0.4%(p 0.03),灵敏度24% vs. 20%(p 0.69),需治疗人数790.5 vs. 415.3。

临床怎么用

  • 入伍前IGRA阳性者被建议在入伍前接受TBI治疗。
  • 作者认为在健康年轻军人群体中值得考虑提高IGRA治疗TBI的阈值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The interferon-gamma releasing assay (IGRA) has been widely used to diagnose latent tuberculosis infection (TBI). However, there are limited data on the association between performance in the IGRA and risk of tuberculosis disease (TBD), as well as on the appropriate IGRA threshold for initiating TBI treatment. METHODS: The analysis was performed using the IGRA results in the Korean Military Manpower Administration database (January 2017 to December 2021), and TBD cases reported to the Korean Military Medical Command (January 2017 to June 2023). All Korean candidates for 18-month military service underwent the IGRA in the pre-enlistment examination, and enlistees who tested positive (≥0.35 IU/mL) were advised to receive TBI treatment before enlistment. RESULTS: From 2017 to 2021, 1 647 941 individuals were screened, with 29 574 testing positive for IGRA. Excluding nonenlistees namely individuals with TBD before enlistment, 19 387 individuals were IGRA positive and 1 356 324 IGRA negative. Of the positives, 4351 were excluded due to discontinued or ongoing TBI treatment at or after enlistment. During follow-up of 9219 untreated and 5818 treated positive individuals and 1 356 324 negatives, TBD occurred in 22 of the IGRA-positive individuals (97.5/100 000 person-years [95% CI, 61.1-147.7]), predominantly in the untreated group (18 cases, 130.1/100 000 person-years [95% CI, 77.1-205.7]) compared to the treated group (4 cases, 45.9/100 000 person-years [95% CI 12.5 - 117.4]), whereas 57 cases occurred in the IGRA-negative group (2.8/100 000 person-years [95% CI, 2.2-3.6]). Elevating the cutoff of IGRA from 0.35 IU/mL to 1.33 IU/mL increased positive predictive value (0.2% vs. 0.4%, p 0.03), with insignificant loss of sensitivity (24% vs. 20%, p 0.69) and decreased numbers needing treatment from 790.5 to 415.3. DISCUSSION: Elevated IGRA levels before enlistment are associated with risk of TBD during military service. It is worth considering raising the IGRA threshold for treatment of TBI in cohorts of healthy, young military individuals.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Kang SW, Lee J, Kim SM, et al. Quantitative interferon-gamma releasing assay in predicting tuberculosis in South Korean military: a retrospective cohort study. Clin Microbiol Infect. 2024. PMID: 38697393. doi:10.1016/j.cmi.2024.04.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。